Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family
Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts
We understand that weight management is not simply about appearance, but about achieving harmony between how you feel and how you look
The Food and Drug Administration (FDA) approved orforglipron for weight loss in April, based on results from the first part of the randomized, double-blinded placebo-controlled clinical trial
How to get enough protein on semaglutide
2 It is the conductor in the orchestra of our circadian rhythm
